Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG1205 in Idiopathic Pulmonary Fibrosis
NCT03725852Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Sep 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of GLPG1205 in idiopathic pulmonary fibrosis (IPF), sponsored by Galapagos NV. Started Sep 2018; status: completed.
02
Drugs
GLPG1205
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03725852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03725852.